Latest profit margin for Opus Genetics: -2182.23% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for IRD is -2182.23% as of September 2026. That compares with 1571.42% in the prior-year period — down 238.9% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Opus Genetics's historical trend and sector peers before judging valuation or financial health.
Over the past year, IRD's profit margin moved from 1571.42% to -2182.23% — a 238.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Opus Genetics's valuation or profitability profile.
Against Healthcare companies, IRD currently prints -2182.23% for profit margin, while the sector average sits near 17.63%. That is roughly 12479.0% below the sector mean. Large gaps often invite a closer look at Opus Genetics's growth, margins, and balance sheet.
Profit Margin shows how effectively Opus Genetics converts resources into returns. At -2182.23%, IRD may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 1571.42% in the prior-year period — down 238.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting IRD's profit margin (-2182.23%), review year-over-year change from 1571.42%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.